Effects of bevacizumab and hyperthermia in a rodent model of hyperthermic intraperitoneal chemotherapy (HIPEC)

International Journal of Hyperthermia

Volumn 29, Issue 1, 2013, Pages 62-70

  Verhulst, Johanna ^a  

^a Independent Researcher   (Belgium)

Author keywords

Bevacizumab; HIPEC; Hyperthermia; Peritoneal carcinomatosis

Indexed keywords

BEVACIZUMAB; OXALIPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; MALE; NONHUMAN; PERFUSION; PREOPERATIVE TREATMENT; RAT; TISSUE PRESSURE; TUMOR GROWTH;

EID: 84872338811     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2012.753738     Document Type: Article

References (28)

1. Armstrong DK, Wenzel L, Huang HQ, Baergen R, Lele S, Walker JL, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43
2. Elias D, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681-685
3. Glehen O, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, et al. Toward curative treatment of peritoneal carcinomatosis from non-ovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Cancer 2010;116:5608-5618
4. Levi F, Metzger G, Massari C, Milano G. Oxaliplatin: Pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 2000;38:1-21
5. Chua I. Adjuvant therapy in colorectal cancer - What, when and how? Ann Oncol 2006;17:1347-1359
6. Frenel JS, Pouplin L, Ferron G, Rigaud DB, Bourbouloux E, Dravet F, et al. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients. J Surg Oncol 2011;103:10-16
7. Cunningham D, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46
8. Fennell DA, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, Nystrom ML, et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural meothelioma. Lung Cancer 2005;47:277-281
9. Tannock IF, Tunggal JK, Cowan DSM, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: A potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002;8:878-884
10. Wijmans JG, Baker RW. The solution-diffusion model: A review. J Membr Science 1995;107:1-21
11. Heldin C-H, Rubin K, Pietras K, O? stman A. High interstitial fluid pressure - An obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-813
12. Willett CG, Boucher Y, di Tomaso E, Dudal DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147
13. Borkamo E, Fluge O, Mella O, Akslen L, Bruland O, Dahl O. Hyperthermia improves the antitumor effect of metronomic cyclophosphamide in a rat transplantable brain tumor. Radiother Oncol 2008;86:435-442
14. Lui P, Fan Y, Xu G, Ngai C, Fung K, Tse G, et al. Apoptotic and necrotic effects of tumour necrosis factor-Alpha potentiated with hyperthermia on L929 and tumour necrosis factoralpha-resistant L929. Int J Hyperthermia 2010;26:556-564
15. Roth M, Zhong J, Tamm M, Szilard J. Mesothelioma cells escape heat stress by upregulating Hsp40/Hsp70 expression via mitogen-Activated protein kinases. J Biomed Biotech 2009:451084
16. Pih N, Sidris L, Pichette V, Drolet P, Fortier LP, Mitchell A, et al. Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis. Ann Surg 2011;254:138-144
17. Pelz J, Doerfer J, Decker M, Dimmler A, Hohenberger W, Meyer T. Hyperthermic intraperitoneal chemoperfusion (HIPEC) decreases wound strength of colonic anastomosis in a rat model. Int J Colorectal Dis 2007;22:941-947
18. Aarts F, Bleichrodt R, Man BD, Lomme R, Boerman O, Hendriks T. The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat. Ann Surg Oncol 2008;15:3299-3307
19. Shimizu T, Maeta M, Koga S. Influence of local hyperthermia on the healing of small intestinal anastomoses in the rat. Br J Surg 1991;78:57-59
20. Klaver YLB, Lomme RMLM, Rutten HJT, Bleichrodt RP, de Hingh IHJT. Hyperthermia and intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis. Ann Surg 2011;254:125-130
21. Saxena A, Yan T, Chua T, Morris D. Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2010;17:1291-1301
22. Spector WS. Handbook of Biological Data. Philadelphia and London: Saunders; 1956
23. Gholap D, Verhulst J, Ceelen WP, Vanhaecke F. A combination of pneumatic nebulization and laser ablation inductively coupled plasma - Mass spectrometry (LA-ICP-MS) for studying the efficacy of intraperitoneal use of a PT-containing chemotherapeutic drug. Anal Bioanal Chem 2012;402:2121-2129
24. Ozerdem U. Measuring interstitial fluid pressure with fiberoptic pressure transducers. Microvasc Res 2009;77:226-229
25. Agrawal S, Tessamani J, Tang JY. Yagi Y, Fushida S, Harada S, et al. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemother Pharmacol 2010;66:745-753
26. Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia 2007;23:431-442
27. Cao C, Yan TD, Black D, Morris DL. A systematic review and meta-Analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2009;16:2152-2165
28. Quenet F, Goere D, Mehta SS, Roca L, Dumont F, Hessissen M, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg 2011;254:294-301